Drug Trial Radar · NCT03808870
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Aug 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Dec 28, 2018
Primary completion
Feb 12, 2022
Study completion Feb 16, 2022
Sponsor
- Lead sponsor
- NatureWise Biotech & Medicals CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jan 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NBM-BMX is an orally available new chemical entity to inhibit HDAC8 activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. The objectives of this study are to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors (Arm A) or in combination with the standard of care treatment (i.e., concomitant RT/TMZ followed by adjuvant TMZ) in subjects with newly diagnosed glioblastoma (Arm B).
Conditions
- Malignant Neoplasm
Interventions
NBM-BMX softgel capsulesDrug
Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT) of NBM-BMX [Safety and Tolerability]Time frame: up to 28 days
- Maximum tolerated dose (MTD) of NBM-BMX [Safety and Tolerability]Time frame: up to 28 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National Cheng Kung University Hospital
Tainan, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.